Full Press Release Details
FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia.
BIIB
FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia
Key Takeaway: FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis